The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma
about
Pathways and therapeutic targets in melanomaARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaThe phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Genomic, prognostic, and cell-signaling advances in uveal melanoma.Combined PKC and MEK inhibition for treating metastatic uveal melanomaCombined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome.Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.Specifying protein kinase C functions in melanoma.Melanoma mutagenesis and aberrant cell signaling.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Novel mouse model for primary uveal melanoma: a pilot study.Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.INPP4B suppresses prostate cancer cell invasionSingle-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structuresGenomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.Synergy between enzastaurin doxorubicin in inducing melanoma apoptosis.Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms.Recent advances in uveal melanoma treatment.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.
P2860
Q26865736-2C171F78-EB64-4D2E-A0AF-99E7F0D08EC1Q28115305-AA23B2E5-A868-46BC-B6AB-44C75B7A41DFQ34096861-6A3E464A-EC81-41B7-A457-570864CB6C92Q35018336-37DC37C8-6973-4715-9694-1BF353EC8A15Q35079709-182C3DA5-6EF0-43A3-B84D-E435E32DECEDQ35163192-FBBB9B74-2C1A-4C63-B307-C2C26E3A9486Q35168515-FDED3D11-342B-43B7-9E7C-06E91004CCE4Q35915107-F59AF16B-4D42-43A2-81F8-595F77FF2E3FQ36210344-21A1E376-61F5-41E5-B1B1-2695AF05955CQ36699796-A6BEFA9B-D240-405A-9BE0-4466B4DCDB2FQ37137610-2951553A-8A43-4D34-9CD0-B5AD5B66751EQ37691937-6670269B-F4BE-4771-A892-7200B0E1DD19Q38009398-FAFA5F35-BC76-4B48-BEF0-84CC627879C1Q38146707-B98D3402-A738-4A14-8F27-EA99D757D89AQ38221107-977E9258-B503-48F9-BD75-E2966A1D7FE6Q38297995-8A343AC4-8B26-44E6-A15A-40E67FAB5CB6Q38646057-D65D9C46-DD69-47E3-9428-54F26D8D6725Q38689912-20AA355D-454E-4332-B575-E3DA071EBC04Q38752881-022B1C73-D5F7-4071-B44F-5E4D33A08D74Q38833742-15718648-A335-4B86-B489-006D7C79C2B2Q38836825-46ED5BAF-9832-45A3-B375-A0C50DD9FA54Q38940707-7392F3E5-0760-4408-9363-36CA1D11587DQ38953956-35CD5833-992C-44E7-9B6C-6D1B1E20377DQ39027262-C12C3BE7-D364-47E9-8E9A-3E8EFD0FB7E9Q39035993-900EADE4-7D68-4F47-B81B-6A40A7D0EDA6Q39124162-899B9809-6793-4C03-BD98-0DEB54C80F25Q41609825-C4524E61-3EDF-427A-9B6B-6886955E207EQ41859238-C3EBCAD4-C17F-4879-B45D-8E2FA8FFA0C0Q43729298-AF148DA6-3F76-4119-B2BC-3375375D7786Q47571643-2B1831D3-08AE-4A19-8F26-C22F77257316Q50102285-C259C359-EC84-4854-9403-2C744F27BBF9Q54118869-66B97130-2F50-4B51-87AE-6D455E4E9993
P2860
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@ast
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@en
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@nl
type
label
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@ast
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@en
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@nl
prefLabel
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@ast
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@en
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@nl
P2093
P2860
P1433
P1476
The protein kinase C inhibitor ...... ctivity against uveal melanoma
@en
P2093
Anita Giobbie-Hurder
F Stephen Hodi
Jonathan A Fletcher
Meijun Zhu
P2860
P304
P356
10.1371/JOURNAL.PONE.0029622
P407
P577
2012-01-12T00:00:00Z